Three more biotechs gained value in the aftermarket Friday after pricing upsized IPOs, with proteomics company Seer scoring a triple-digit gain while Silverback and Sigilon each rose by double digits. With the trio’s listings, more...
...Inc. (NYSE:PFE) and the American Hospital Association. Ricchetti headed congressional lobbying for Blue Cross Blue Shield... ...previous years.
Steve Usdin
Eli Lilly and Co.
Pfizer Inc.
Genomics Institute of the Novartis Research Foundation
Blue Cross Blue Shield
Eisai...
Regardless of the outcome of the elections, FDA is likely to have a new commissioner next year, one who will step into a leadership vacuum that is exhausting the agency’s supply of credibility and...
Just hours after Eli Lilly became the first COVID-19 mAb developer to disclose it had requested emergency use authorization, President Donald Trump released a video calling for immediate authorization of both Lilly’s and Regeneron’s mAbs,...
During a House Committee on Energy and Commerce hearing on Wednesday, Paul Offit and Mark McClellan both highlighted multiple “guardrails” designed to protect the COVID-19 vaccine authorization and approval process from political pressure. Committee members’...
As FDA’s October advisory committee meeting on COVID-19 vaccines approaches, at least three standing members have signaled publicly that authorization and distribution of a vaccine should not be rushed without scientific evidence. A roster of the...
The outpatient setting of the first clinical trial of Vir and GSK’s lead antiviral COVID-19 mAb buffers the study from being affected by FDA’s emergency use authorization for convalescent plasma. The partners also differentiated their...
Three more biotechs gained value in the aftermarket Friday after pricing upsized IPOs, with proteomics company Seer scoring a triple-digit gain while Silverback and Sigilon each rose by double digits. With the trio’s listings, more...
...Inc. (NYSE:PFE) and the American Hospital Association. Ricchetti headed congressional lobbying for Blue Cross Blue Shield... ...previous years.
Steve Usdin
Eli Lilly and Co.
Pfizer Inc.
Genomics Institute of the Novartis Research Foundation
Blue Cross Blue Shield
Eisai...
Regardless of the outcome of the elections, FDA is likely to have a new commissioner next year, one who will step into a leadership vacuum that is exhausting the agency’s supply of credibility and...
Just hours after Eli Lilly became the first COVID-19 mAb developer to disclose it had requested emergency use authorization, President Donald Trump released a video calling for immediate authorization of both Lilly’s and Regeneron’s mAbs,...
During a House Committee on Energy and Commerce hearing on Wednesday, Paul Offit and Mark McClellan both highlighted multiple “guardrails” designed to protect the COVID-19 vaccine authorization and approval process from political pressure. Committee members’...
As FDA’s October advisory committee meeting on COVID-19 vaccines approaches, at least three standing members have signaled publicly that authorization and distribution of a vaccine should not be rushed without scientific evidence. A roster of the...
The outpatient setting of the first clinical trial of Vir and GSK’s lead antiviral COVID-19 mAb buffers the study from being affected by FDA’s emergency use authorization for convalescent plasma. The partners also differentiated their...
